EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access · CC BY-NC-ND 4.0

A Phase Ib Case Series Using Bortezomib With Chemotherapy in Atypical Teratoid/Rhabdoid Tumors

Wan-Ling Ho iD, Ming-Yun Hsieh, Yu-Mei Liao, Shyh-Shin Chiou, Her-Shyong Shiah, Chang-Hsu Chiang, Shiann-Tarng Jou, Hsiu-Ju Yen iD, Yi-Yen Lee, Muh-Lii Liang, Ting-Chi Yeh, Yu-Cheng Chou iD und 27 weitere

Cancer Medicine · 2026

DOI: 10.1002/cam4.72173 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Cancer Medicine, 2026. Verfasst von Wan-Ling Ho und 38 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan. Hauptthemen laut MEDLINE: Bortezomib, Rhabdoid Tumor, Teratoma, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Taiwan Ministry of Health and Welfare Clinical Trial Center, 5th National Cancer Control Program, Taipei Municipal Wanfang Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Atypical teratoid/rhabdoid tumors (ATRTs) are aggressive pediatric brain tumors that are sensitive to proteasome inhibitors in preclinical models. We evaluated the feasibility of combining the proteasome inhibitor, bortezomib, with chemotherapy.

Methods

Six patients aged 0.8–13 years with newly diagnosed ATRT were enrolled from January 2022 through December 2023. Bortezomib was given intravenously at the dose of 1.3 mg/m 2 /day on days 1, 4, 8, and 11 of a 21‐day chemotherapy cycle for 6 cycles. Radiation therapy was given before initiation of chemotherapy in 4 patients or at the end of chemotherapy in one patient. The primary endpoint was grade 3 or higher non‐hematologic toxicities.

Results

Thirty cycles of bortezomib with chemotherapy were evaluated. No grade 3 or higher toxicities were considered bortezomib‐related. Four patients completed 6 cycles of bortezomib; 2 patients discontinued treatment due to progressive disease after 2 and 4 cycles, respectively. An additional 6 cycles of bortezomib were evaluated after high‐dose chemotherapy in three patients without grade 4 bortezomib‐related toxicity. Five patients had a near‐total resection; one patient had a subtotal resection. Four patients were evaluable for response with 2 partial responses, 1 stable disease, and 1 progressive disease. Two patients without measurable tumor after surgery were not evaluable for response. Two patients remain alive without disease at 37 and 40 months, and one patient died without disease at 19 months after diagnosis. Three patients died with progressive disease.

Conclusions

The toxicities were no more than expected with chemotherapy alone. Adding bortezomib to treatment of ATRT is feasible. Trial Registration NCT06853080

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BortezomibRhabdoid TumorTeratomaAntineoplastic Combined Chemotherapy ProtocolsBrain NeoplasmsHumansMaleFemaleAdolescentChild, PreschoolChildInfantTreatment OutcomeProteasome Inhibitors

Stichwörter der Autor:innen

atypical teratoid/rhabdoid tumor (ATRT)bortezomibchemotherapyfeasibilityproteasome inhibitors

Substanzen

BortezomibProteasome Inhibitors

Autor:innen und Institutionen

  • Department of Pediatrics, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
  • Department of Pediatrics, Taipei Medical University Hospital, Taipei, Taiwan.
  • Pediatric Brain Tumor Program, Taipei Cancer Center, Taipei Neurological Institute, Taipei Medical University, Taipei, Taiwan.
  • TMU Research Center of Cancer Translational Medicine, Taipei Medical University, Taipei, Taiwan.
  • Department of Pediatrics, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan.
  • Division of Pediatric Hematology and Oncology, Department of Pediatrics, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.

ORCID-Profile: Wan-Ling Ho, Hsiu-Ju Yen, Yu-Cheng Chou, Pei-Chin Lin, Shih-Chung Wang, Yi-Fang Tu, Chao-Neng Cheng, Jimmy Ming-Jung Chuang, Yen-Lin Liu

Förderung

  • Taiwan Ministry of Health and Welfare Clinical Trial Center
  • 5th National Cancer Control Program
  • Taipei Municipal Wanfang Hospital
  • Taipei Medical University Hospital
  • National Science and Technology Council, Taiwan
  • TMU Research Center of Cancer Translational Medicine
  • Ministry of Education
  • Wan Fang Hospital

Zitieren

APA

Ho, W. L., Hsieh, M. Y., Liao, Y. M., Chiou, S. S., Shiah, H. S., Chiang, C. H., Jou, S. T., Yen, H. J., Lee, Y. Y., Liang, M. L., Yeh, T. C., Chou, Y. C., Huang, F. L., Chen, S. H., Lee, H. L., Kuo, C. C., Yang, Y. S., Chen, S. M., Tsai, M. L., …, & Wong, T. T. (2026). A Phase Ib Case Series Using Bortezomib With Chemotherapy in Atypical Teratoid/Rhabdoid Tumors. Cancer Medicine. https://doi.org/10.1002/cam4.72173

Vancouver

Ho WL, Hsieh MY, Liao YM, Chiou SS, Shiah HS, Chiang CH, et al. A Phase Ib Case Series Using Bortezomib With Chemotherapy in Atypical Teratoid/Rhabdoid Tumors. Cancer Medicine. 2026. doi:10.1002/cam4.72173

BibTeX
@article{Ho2026,
  author = {Ho, Wan-Ling and Hsieh, Ming-Yun and Liao, Yu-Mei and Chiou, Shyh-Shin and Shiah, Her-Shyong and Chiang, Chang-Hsu and Jou, Shiann-Tarng and Yen, Hsiu-Ju and Lee, Yi-Yen and Liang, Muh-Lii and Yeh, Ting-Chi and Chou, Yu-Cheng and Huang, Fang-Liang and Chen, Shu-Huey and Lee, Hsin-Lun and Kuo, Chia-Chun and Yang, Yi-Shan and Chen, Shu-Mei and Tsai, Min-Lan and Chang, Hsi and Hsieh, Kevin Li-Chun and Fang, Chia-Lang and Chang, Chia-Yau and Wang, Jinn-Li and Chen, Chu-Chin and Loh, Joon-Khim and Lin, Pei-Chin and Lin, Tzu-Chin and Wang, Shih-Chung and Tu, Yi-Fang and Cheng, Chao-Neng and Chuang, Jimmy Ming-Jung and Tran, Huy Minh and Sung, Shian-Ying and Lai, Irving and Wu, Kuo-Sheng and Miser, James S and Liu, Yen-Lin and Wong, Tai-Tong},
  title = {A Phase Ib Case Series Using Bortezomib With Chemotherapy in Atypical Teratoid/Rhabdoid Tumors},
  journal = {Cancer Medicine},
  year = {2026},
  doi = {10.1002/cam4.72173}
}
Kostenlos starten →